LayerBio to Present Preclinical Results for Extended Release Glaucoma Formulation at ARVO

LayerBio will present preclinical study results at the Association for Research in Vision and Ophthalmology in Honolulu, Hawaii on Monday, April 30. These results demonstrate the therapeutic potential of its novel extended-release travoprost formulation using LayerBio's proprietary PolyNet™ delivery technology.

Honolulu, HI, April 27, 2018 --(PR.com)-- LayerBio will present preclinical study results at the Association for Research in Vision and Ophthalmology in Honolulu, Hawaii on Monday, April 30.

In this study, LayerBio's proprietary intracameral extended-release formulation of the glaucoma drug travoprost is shown to lower intraocular pressure to therapeutic levels for longer than six months.

"Implantable extended release formulations are an emerging class of treatments for glaucoma. Conventional eye drops are often ineffective due to lack of patient compliance with their prescribed regimens," explains Dr. Ken Mandell, LayerBio's CEO. "Furthermore, sustained-release formulations afford 24-hour drug coverage, a distinct advantage over eye drops."

LayerBio's extended-release travoprost formulation is based on its PolyNet™ technology, a proprietary network polymer-based delivery platform invented by Dr. Mandell at LayerBio. PolyNet™ enables tunable control of drug release from a biocompatible, bio-erodible polymer system with a variety of classes of medications for glaucoma and other ophthalmic indications.

"The results presented at ARVO demonstrate the therapeutic advantages of our travoprost formulation and the PolyNet™ platform," commented Dr. Paula Hammond, co-founder of LayerBio and Head of Chemical Engineering at MIT. "LayerBio's technology has the potential to improve the way we treat eye disease."